www.klinickafarmakologie.cz / KlinFarmakol Farm2021; 35(4): 106–111 / KLINICKÁ FARMAKOLOGIE A FARMACIE 111 HLAVNÍ TÉMA Revmatické nežádoucí účinky imunoterapie nádorových onemocnění inhibitory kontrolního bodu imunitních reakcí filtraci jizvy. Mezi další projevy patří artralgie, uveitida, infiltrace parotidy, ledvin či sleziny. V laboratorním vyšetření je možno pozorovat hyperkalcemii i elevaci sérového angiotenzin konvertujícího enzymu (53, 54). Projevy mohou spontánně vymizet po vysazení vyvolávající medikace. U asymptomatického průběhu je ke zvážení pokračování v terapii ICI (54). Symptomatický průběh vyžaduje nasazení p. o. prednisonu v dávce 20–60mg/den dle závažnosti stavu. Měla by být snaha o pokračování v léčbě ICI při dávce prednisonu <10mg/den (2). Metotrexát v dávce 12,5mg/týden a infliximab v dávce 5mg/kg byly použity pouze u neurosarkoidózy (55, 56). LITERATURA 1. Suarez-Almazor ME, Kim ST, et al. Review: Immune-Related Adverse Events With Use of Checkpoint Inhibitors for Immunotherapy of Cancer. Arthritis and Rheumatology. 2017;69(4):687–699. 2. Kostine M, Finckh A, et al. EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors. Ann Rheum Dis. 2021;80(1):36–48. 3. PostowM, Sidlow R, et al. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. N Engl J Med. 2018;378(2):158–68. 4. Das S, Johnson D. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. Journal for ImmunoTherapy of Cancer. 2019;7(1):306. 5. Brahmer J, Lacchetti C, McDermott DF, et al. National Comprehensive Cancer Network. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018;36(17):1714–1768. 6. Thompson J, Schneider B, NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020;18(3):230–241. 7. Haanen J, Carbonnel F, et al. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology. 2017;28:iv119–142. 8. Calabrese L, Velcheti V. Checkpoint immunotherapy: Good for cancer therapy, bad for rheumatic diseases. Vol. 76, Ann Oncol. 2017;76(1):1–3. 9. Leipe J, Christ LA, Arnoldi AP, Mille E, Berger F, Heppt M, et al. Characteristics and treatment of new-onset arthritis after checkpoint inhibitor therapy. RMD Open. 2018;4(2):e000714. 10. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE – Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr (Engl Ed). 2021;112(1):90–92. 11. Arbour K, Mezquita L, et al. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. J Clin Oncol. 2018;36(28):2872–2878. 12. Salem J-E, Allenbach Y, et al. Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis. N Engl J Med. 2019;380(24):2377–2379. 13. Lidar M, Giat E, et al. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors. Autoimmunity Reviews. 2018;17(3):284–289. 14. Leipe J, Mariette X. Management of rheumatic complications of ICI therapy: A rheumatology viewpoint. Rheumatology (United Kingdom). 2019;58: vii49–58. 15. Abdel-Wahab N, Suarez-Almazor ME. Frequency and distribution of various rheumatic disorders associated with checkpoint inhibitor therapy. Rheumatology (United Kingdom). 2019;58: vii40–48. 16. Braaten TJ, Brahmer JR, et al. Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation. Ann Rheum Dis. 2020;79(3):332–338. 17. Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-An overview. Rheumatology (United Kingdom). 2019;58:vii7–16. 18. StevenNM, Fisher BA. Management of rheumatic complications of immune checkpoint inhibitor therapy-An oncological perspective. Rheumatology (United Kingdom). 2019;58:vii29–39. 19. Kostine M, Truchetet ME, Schaeverbeke T. Clinical characteristics of rheumatic syndromes associated with checkpoint inhibitors therapy. Rheumatology (United Kingdom). 2019;58:vii68–74. 20. Smolen JS, Landewé RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020;79(6):S685–99. 21. Strangfeld A, Richter A, et al. Risk for lower intestinal perforations in patients with rheumatoid arthritis treated with tocilizumab in comparison to treatment with other biologic or conventional synthetic DMARDs. Annals of the Rheumatic Diseases. 2017;76(3):504–510. 22. Champiat S, Lambotte O, et al. Management of Immune Checkpoint Blockade Dysimmune Toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574. 23. Dasgupta B, Cimmino MA, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis. 2012 ;71(4):484–492. 24. Rehak Z, Sprlakova-Pukova A, Kazda T, Fojtik Z, Vargova L, Nemec P. 18F-FDG PET/CT in polymyalgia rheumatica-a pictorial review. Br J Radiol. 2017;90(1076):20170198. 25. Pavelka K, et al. Revmatologie Praha: Maxdorf, 2018:507–529 26. Hellmich B, Agueda A, et al. 2018 Update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis.2020;79(1):19–130. 27. Stone JH, Tuckwell K, et al. Trial of Tocilizumab in Giant- -Cell Arteritis. N Engl J Med. 2017;377(4):317–328. 28. Solimando AG, Crudele L,et al. Immune checkpoint inhibitor-related myositis: From biology to bedside. Int J Mol Sci. 2020;21(9):3054. 29. Matsui H, Kawai T, et al. A fatal case of myocarditis following myositis induced by pembrolizumab treatment for metastatic upper urinary tract urothelial carcinoma. International Heart Journal. 2020;61(5):1070–1074. 30. Bednařík J, Ambler Z, Růžička E. Klinická neurologie, část speciální II. Praha: Triton, 2010:980–982. 31. Johnson DB, Balko JM, et al. Fulminant Myocarditis with Combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749–1755. 32. Calabrese LH, Calabrese C, Cappelli LC. Rheumatic immune-related adverse events from cancer immunotherapy. Nat Rev Rheumatol. 2018;14(10):569–579. 33. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. 2017;82:34–44. 34. Warner BM, Baer AN, et al. Sicca Syndrome Associated with Immune Checkpoint Inhibitor Therapy. The Oncologist. 2019;24(9):1259–1269. 35. Ghosn J, Vicino A, et al. A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab. J Immunother Cancer. 2018;6(1):110 36. James-Goulbourne T, Murugesan V, Kissin EY. Sonographic Features of Salivary Glands in Sjögren’s Syndrome and its Mimics. Curr Rheumatol Rep. 2020;22(8):36. 37. Mavragani CP, Moutsopoulos HM. Sicca syndrome following immune checkpoint inhibition. Clin Immunol. 2020;217:108497. 38. Ghosn J, Vicino A, et al. A severe case of neuro-Sjögren’s syndrome induced by pembrolizumab. J Immunother Cancer. 2018;22;6(1). 39. Daxini A, Cronin K, et al. Vasculitis associated with immune checkpoint inhibitors – a systematic review. Clin Rheumatol. 2018;37(9):2579–2584. 40. Crout TM, Lennep DS, Kishore S, Majithia V. Systemic Vasculitis Associated With Immune Check Point Inhibition: Analysis and Review. Curr Rheumatol Rep. 201921;21(6):28. 41. Tomelleri A, Campochiaro C, de Luca G, Cavalli G, Dagna L. Anti-PD1 therapy-associated cutaneous leucocytoclastic vasculitis: A case series. Eur J Intern Med. 2018;57:e11–e12. 42. Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Ipilimumab induced digital vasculitis. Journal for ImmunoTherapy of Cancer. 2018;6(1):12. 43. Michot JM, Fusellier M, et al. Drug-induced lupus erythematosus following immunotherapy with anti-programmed death-(ligand) 1. Ann Rheum Dis. 2019;78(7):e67. 44. Fadel F, El Karoui K, Knebelmann B. Anti-CTLA4 antibody- -induced lupus nephritis. N Engl J Med. 2009;361(2):211–212. 45. Gupta A, Shah U, Khine H, Vandergriff T, Froehlich T. Antiphospholipid syndrome associated with combined immune checkpoint inhibitor therapy. Melanoma Res. 2017;27(2):171– 173. 46. Owosho AA, Scordo M, Yom SK, Randazzo J, Chapman PB, Huryn JM, et al. Osteonecrosis of the jaw a new complication related to Ipilimumab. Oral Oncol. 2015;51(12):e100–101. 47. Moseley KF, Naidoo J, Bingham CO, Carducci MA, Forde PM, Gibney GT, et al. Immune-related adverse events with immune checkpoint inhibitors affecting the skeleton: A seminal case series 11 Medical and Health Sciences 1103 Clinical Sciences. Journal for ImmunoTherapy of Cancer. 2018;6(1):104 48. Barbosa NS, Wetter DA, et al. Scleroderma Induced by Pembrolizumab: A Case Series. Mayo Clinic Proceedings. 2017;92(7):1158–1163. 49. Tjarks BJ, Kerkvliet AM, Jassim AD, Bleeker JS. Scleroderma-like skin changes induced by checkpoint inhibitor therapy. Journal of Cutaneous Pathology. 2018;45(8):615–618. 50. Shenoy N, Esplin B, Barbosa N. Pembrolizumab induced severe sclerodermoid reaction. Journal of Clinical Oncology. 2016;34(32):3838–3845. 51. Chan KK, Magro C, et al. Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature. The Oncologist. 2020;25(2):140–149. 52. Salamaliki C, Solomou EE, Liossis SNC. Immune Checkpoint Inhibitor-Associated Scleroderma-Like Syndrome: A Report of a Pembrolizumab-Induced “Eosinophilic Fasciitis-Like” Case and a Review of the Literature. Rheumatology and Therapy. 2020;7(4):1045–1052. 53. Apalla Z, Kemanetzi C, et al. Challenges in sarcoidosis and sarcoid-like reactions associated to immune checkpoint inhibitors: A narrative review apropos of a case. Dermatol Ther. 2021;34(1):e14618. 54. Chopra A, Nautiyal A, Kalkanis A, Judson MA. Drug-Induced Sarcoidosis-Like Reactions. Vol. 154, Chest. 2018;154(3):664–677. 55. Dunn-Pirio AM, Shah S, Eckstein C. Neurosarcoidosis following Immune Checkpoint Inhibition. Case Rep Oncol. 2018;11(2):521–526. 56. Tan I, Malinzak M, et al. Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy. J Immunother Cancer. 2018;6(1):77.
RkJQdWJsaXNoZXIy NDA4Mjc=